Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

García-Romero, Noemí; Palacín-Aliana, Irina; Madurga, Rodrigo; Carrión-Navarro, Josefa; Esteban-Rubio, Susana; Jiménez, Beatriz; Collazo, Ana; Pérez-Rodríguez, Francisco-Javier; Méndivil, Ana Ortiz de; Fernández-Carballal, C.; García-Duque, Sara; Diamantopoulos-Fernández, J.; Belda-Iniesta, Cristóbal; Prat-Acín, Ricardo; Sánchez-Gómez, Pilar; Calvo, Emiliano; Ayuso-Sacido, Ángel

doi:10.1186/s12916-020-01610-0

Cited by 27 publications

(24 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Found that anti-angiogenic effect (VEGFA expression levels) the response to treatment in cell culture. This data indicate that bevacizumab can improve clinical results in Glioblastoma therapy (27).…”

Section: Acknowledgmentmentioning

confidence: 68%

The Use of Bevacizumab Alone and in Combination With Classical Chemotheropathics in Ishikawa Endometrial Cancer Cell Culture

Eren¹,

Gurer²,

Gürsoy³

et al. 2021

Acibadem Universitesi Saglik Bilimleri Dergisi

View full text Add to dashboard Cite

The aim of our study is to determine the effects of an antiangiogenic agent (bevacizumab) in combination with or without classic chemotherapeutics on the endometrium carcinoma and use these information in our clinic practice. Materials and Methods:In vitro tests were done to determine the cytotoxic and apoptotic effects of Cisplatin, Adriablastine and Bevacizumab. Cytotoxic effect was determined by the standard MTT assay (Tetrozolium Test) and apopthosis by DAPI staining, caspase-3 on human endometrium cancer cell culture (Ishikawa). Results:The MTT assay determined that 9.6 mg/ml dose of bevacizumab caused a higher rate of decrease in cell number on Ishikawa cells compared to the highest doses of Cisplatin and Adriablastine. Therewithal, when Bevacizumab, Cisplatin, and Adriablastine were applied together for 24 hours, the number of cells decreased with an increasing dose. With the use of the triple combination with DAPI staining, it is seen that the cell silhouettes are effaced and the findings indicating apoptosis become more apparent. When bevacizumab was applied alone, the caspase 3 activity it produced was ascertained to be higher than the other two drugs individually and in combination. Caspase-3 activity was ascertained to have increased significantly as a result of the collective usage of 40 µM Cisplatin + 20 µM Adriablastine + 9.6 µgram / ml Bevacizumab, and this was found to be the highest cytotoxic activity compared to other applications. Conclusion:Bevacizumab has significant anticancer activity alone or in combination with other chemotherapeutics.

show abstract

Section: Acknowledgmentmentioning

confidence: 68%

The Use of Bevacizumab Alone and in Combination With Classical Chemotheropathics in Ishikawa Endometrial Cancer Cell Culture

Eren¹,

Gurer²,

Gürsoy³

et al. 2021

Acibadem Universitesi Saglik Bilimleri Dergisi

View full text Add to dashboard Cite

show abstract

“…Consistent with this framework, mouse studies have shown dose-dependent effects of bevacizumab on tumor cells and vasculature. 34 , 35 Future studies will need to explore whether shorter-term survivors have fewer VEGFA receptors and would benefit from reduced bevacizumab dosing to shift tumor physiology from vascular pruning to normalization.…”

Section: Discussionmentioning

confidence: 99%

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma

Talati

El-Abtah

Kim

et al. 2021

Neuro-Oncology Advances

View full text Add to dashboard Cite

Background Determining failure to anti-angiogenic therapy in recurrent GBM (rGBM) remains a challenge. The purpose of the study was to assess treatment response to bevacizumab-based therapy in patients with rGBM using MR spectroscopy (MRS). Methods We performed longitudinal MRI/MRS in 33 patients with rGBM to investigate whether changes in N-acetylaspartate (NAA)/Choline (Cho) and Lactate (Lac)/NAA from baseline to subsequent time points after treatment can predict early failures to bevacizumab-based therapies. Results After stratifying based on 9 month survival, longer-term survivors had increased NAA/Cho and decreased Lac/NAA levels compared to shorter-term survivors. ROC analyses for intratumoral NAA/Cho correlated with survival at 1 day, 2 weeks, 8 weeks, and 16 weeks. Intratumoral Lac/NAA ROC analyses were predictive of survival at all time points tested. At the 8 week time point, 88% of patients with decreased NAA/Cho did not survive 9 months; furthermore, 90% of individuals with an increased Lac/NAA from baseline did not survive at 9 months. No other metabolic ratios tested significantly predicted survival. Conclusions Changes in metabolic levels of tumoral NAA/Cho and Lac/NAA can serve as early biomarkers for predicting treatment failure to anti-angiogenic therapy as soon as 1 day after bevacizumab-based therapy. The addition of MRS to conventional MR methods can provide better insight into how anti-angiogenic therapy affects tumor microenvironment and predict patient outcomes.

show abstract

“…Of primary GBs, 80% were found to express VEGFA. A potential relationship could reveal a subgroup of GB patients who might benefit from a therapy with angiogenesis inhibitors ( 45 ). MPV/PC ratio seems to be a promising biomarker for the activity of platelets.…”

Section: Discussionmentioning

confidence: 99%

Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma

et al. 2021

View full text Add to dashboard Cite

ObjectiveThe mean platelet volume/platelet count (MPV/PC) ratio is an emerging biomarker in selected types of cancer. The objective of this study is to analyze the association of MPV/PC ratio with progression and survival in glioblastoma (GB) patients, with consideration of patient demographics, tumor morphology, extent of resection, molecular pathology, and oncological therapy.MethodsOne hundred ninety-one patients with newly diagnosed GB were analyzed retrospectively. MPV/PC ratio groups (≤ or >0.0575) were dichotomized into low-MPV/PC ratio (≤0.0575) and high-MPV/PC ratio (>0.0575) groups according to the most significant split in the log-rank test.ResultsA two-sided Fisher’s exact test showed no significant differences in the confounders between the low- and high-MPV/PC ratio groups. The median progression-free survival (PFS) was 9.0 months (95% CI=8.0–10.0) in the low-MPV/PC ratio group (n=164) and 6.0 months (95% CI=3.0–8.9) in the high-MPV/PC group (n=28) (p=0.013). Multivariate Cox regression analysis including the O-6-methylguanine-DNA methyltransferase (MGMT) status, age (≤/>65 years), baseline Karnofsky Performance Status (KPS), and MPV/PC ratio showed high-MPV/PC ratio as a predictor of progression (p =0.04, HR=1.61, 95% CI=1.01–2.57). In the subgroup of IDH1 wild-type GBs, high MPV/PC ratio was still a significant predictor for shortened PFS (p=0.042, HR=1.60, 95% CI=1.02–2.52). MPV/PC ratio showed no significant effect in the overall survival (OS) analysis. Median OS was 15.0 months in the high-MPV/PC ratio group and 21.0 months in the low-MPV/PC ratio group (p=0.22).ConclusionMPV/PC ratio may independently predict the progression-free survival rates of patients with glioblastoma multiforme.

show abstract

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Cited by 27 publications

References 50 publications

The Use of Bevacizumab Alone and in Combination With Classical Chemotheropathics in Ishikawa Endometrial Cancer Cell Culture

The Use of Bevacizumab Alone and in Combination With Classical Chemotheropathics in Ishikawa Endometrial Cancer Cell Culture

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma

Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma

Contact Info

Product

Resources

About